Clinical Trials Directory

Trials / Terminated

TerminatedNCT01188369

Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy

Effects of Levosimendan on Systolic Deformation and Diastolic Function in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
20 (actual)
Sponsor
University of Aarhus · Academic / Other
Sex
All
Age
30 Years – 90 Years
Healthy volunteers
Not accepted

Summary

This is a clinical, randomised, double-blinded study in which patients eligible for aortic valve replacement are enrolled. Patients receive infusion of either levosimendan or placebo 4 hours prior to surgery and until the end of surgery.

Detailed description

Levosimendan or placebo will be infusion for approximately 4 hours prior to aortic valve replacement in patients with severe hypertrophy of the left ventricle and echocardiographic signs of diastolic dysfunction. Outcome measures will be obtained at some of the following: * Approximately 4 hours prior to surgery. Baseline. Start of levosimendan/placebo infusion * Immediately before surgery * After induction of anaesthesia and before "knife time" = start of surgery. * At the end of surgery: Levosimendan infusion will stop. * Approximately 4 hours after surgery immediately before extubation. * Approximately 21 hours after surgery * Approximately 96 hours after surgery (day 4) * 6 months after surgery Outcome measures are comprised of invasive measurements, blood samples, transthoracic echocardiography and transoesophageal echocardiography focusing on measures of systolic and diastolic function of the heart. Interim analysis will be conducted after 30 included patients.

Conditions

Interventions

TypeNameDescription
DRUGlevosimendanIntravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
DRUGplacebo drugIntravenous infusion, colour identical to levosimendan

Timeline

Start date
2010-09-01
Primary completion
2013-03-01
Completion
2013-03-01
First posted
2010-08-25
Last updated
2018-12-03
Results posted
2018-12-03

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01188369. Inclusion in this directory is not an endorsement.